200 related articles for article (PubMed ID: 18328090)
1. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
[TBL] [Abstract][Full Text] [Related]
2. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Lehmann R; Brzosko M; Kopsa P; Nischik R; Kreisse A; Thurston H; Litschig S; Sloan VS
Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
[TBL] [Abstract][Full Text] [Related]
4. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Dougados M; Moore A; Yu S; Gitton X
Arthritis Res Ther; 2007; 9(1):R11. PubMed ID: 17266764
[TBL] [Abstract][Full Text] [Related]
7. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
[TBL] [Abstract][Full Text] [Related]
8. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Stricker K; Yu S; Krammer G
BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
[TBL] [Abstract][Full Text] [Related]
9. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
Schnitzer TJ; Dattani ID; Seriolo B; Schneider H; Moore A; Tseng L; Sallstig P; Rebuli R; Maxwell T
Clin Rheumatol; 2011 Nov; 30(11):1433-46. PubMed ID: 21607551
[TBL] [Abstract][Full Text] [Related]
10. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
Fricke J; Davis N; Yu V; Krammer G
J Pain; 2008 Jan; 9(1):20-7. PubMed ID: 17933588
[TBL] [Abstract][Full Text] [Related]
11. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
Dahlberg LE; Holme I; Høye K; Ringertz B
Scand J Rheumatol; 2009; 38(2):133-43. PubMed ID: 19165648
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.
Sheldon EA; Beaulieu A; Paster Z; Yu S; Rebuli R
Clin Exp Rheumatol; 2008; 26(4):611-9. PubMed ID: 18799092
[TBL] [Abstract][Full Text] [Related]
13. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
Grifka JK; Zacher J; Brown JP; Seriolo B; Lee A; Moore A; Gimona A
Clin Exp Rheumatol; 2004; 22(5):589-96. PubMed ID: 15485012
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Daniels S; Gitton X; Zhou W; Stricker K; Barton S
J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
